Treatment options after sorafenib failure in patients with hepatocellular carcinoma

被引：31

作者：

El Dika, Imane ^{[1
]}

Abou-Alfa, Ghassan K. ^{[1
,2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 300 East 66th St, New York, NY 10065 USA

[2] Weill Cornell Med Coll, New York, NY USA

来源：

CLINICAL AND MOLECULAR HEPATOLOGY | 2017年 / 23卷 / 04期

关键词：

Hepatocellular carcinoma; Antiangiogenic therapy; MET-inhibitors; Immunotherapy; RECOMBINANT HUMAN ARGINASE; PHASE-II; HEPATITIS-C; 2ND-LINE TREATMENT; FUTURE-DIRECTIONS; CLINICAL-TRIAL; DOUBLE-BLIND; THERAPY; ANGIOGENESIS; EFFICACY;

D O I：

10.3350/cmh.2017.0108

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellular carcinoma in the world, continued efforts are ongoing to look for efficient upfront, second line, or combination therapies. Herein we review the most relevant to date published literature on treatment options beyond sorafenib, reported studies, ongoing investigational efforts, and possibilities for future studies in advanced hepatocellular carcinoma.

引用

页码：273 / 279

页数：7

共 47 条

[11] Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship With Clinical and Pathological Features [J].

Calderaro, Julien ;

Rousseau, Benoit ;

Amaddeo, Giuliana ;

Mercey, Marion ;

Charpy, Cecile ;

Costentin, Charlotte ;

Luciani, Alain ;

Zafrani, Elie-Serge ;

Laurent, Alexis ;

Azoulay, Daniel ;

Lafdil, Fouad ;

Pawlotsky, Jean-Michel .

HEPATOLOGY, 2016, 64 (06) :2038-2046

[12] Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint [J].

Chen, Jiang ;

Ji, Tong ;

Zhao, Jie ;

Li, Gaofeng ;

Zhang, Jian ;

Jin, Renan ;

Liu, Jinghua ;

Liu, Xiaolong ;

Liang, Xiao ;

Huang, Diyu ;

Xie, Anyong ;

Lin, Hui ;

Cang, Yong ;

Cai, Xiujun .

ONCOTARGET, 2016, 7 (27) :41274-41284

[13] Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). [J].

Cheng, Ann-Lii ;

Finn, Richard S. ;

Qin, Shukui ;

Han, Kwang-Hyub ;

Ikeda, Kenji ;

Piscaglia, Fabio ;

Baron, Ari David ;

Park, Joong-Won ;

Han, Guohong ;

Jassem, Jacek ;

Blanc, Jean -Frederic ;

Vogel, Arndt ;

Komov, Dmitry ;

Evans, T. R. Jeffry ;

-Lopez, Carlos Lopez ;

Dutcus, Corina E. ;

Ren, Min ;

Kraljevic, Silvija ;

Tamai, Toshiyuki ;

Kudo, Masatoshi .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[14] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Chen, Zhendong ;

Tsao, Chao-Jung ;

Qin, Shukui ;

Kim, Jun Suk ;

Luo, Rongcheng ;

Feng, Jifeng ;

Ye, Shenglong ;

Yang, Tsai-Sheng ;

Xu, Jianming ;

Sun, Yan ;

Liang, Houjie ;

Liu, Jiwei ;

Wang, Jiejun ;

Tak, Won Young ;

Pan, Hongming ;

Burock, Karin ;

Zou, Jessie ;

Voliotis, Dimitris ;

Guan, Zhongzhen .

LANCET ONCOLOGY, 2009, 10 (01) :25-34

[15] Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion [J].

Cheng, Paul Ning-Man ;

Lam, Tin-Lun ;

Lam, Wai-Man ;

Tsui, Sam-Mui ;

Cheng, Anthony Wai-Ming ;

Lo, Wai-Hung ;

Leung, Yun-Chung .

CANCER RESEARCH, 2007, 67 (01) :309-317

[16]

Chow AKM, 2012, CURR CANCER DRUG TAR, V12, P1233

[17] Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT) [J].

Cohn, Allen Lee ;

Kelley, Robin Katie ;

Yang, Tsai-Shen ;

Su, Wu-Chou ;

Verslype, Chris ;

Ramies, David A. ;

Lee, Yihua ;

Shen, Xiaodong ;

Van Cutsem, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)

[18] Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines [J].

D'Alessandro, Rosalba ;

Refolo, Maria G. ;

Lippolis, Catia ;

Giannuzzi, Grazia ;

Carella, Nicola ;

Messa, Caterina ;

Cavallini, Aldo ;

Carr, Brian I. .

BMC CANCER, 2014, 14

[19] Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy [J].

Dvorak, HF .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4368-4380

[20] Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].

El-Khoueiry, Anthony B. ;

Sangro, Bruno ;

Yau, Thomas ;

Crocenzi, Todd S. ;

Kudo, Masatoshi ;

Hsu, Chiun ;

Kim, Tae-You ;

Choo, Su-Pin ;

Trojan, Jorg ;

Welling, Theodore H., III ;

Meyer, Tim ;

Kang, Yoon-Koo ;

Yeo, Winnie ;

Chopra, Akhil ;

Anderson, Jeffrey ;

dela Cruz, Christine ;

Lang, Lixin ;

Neely, Jaclyn ;

Tang, Hao ;

Dastani, Homa B. ;

Melero, Ignacio .

LANCET, 2017, 389 (10088) :2492-2502

← 1 2 3 4 5 →